Suppr超能文献

门冬胰岛素:综述

Insulin aspart: a review.

作者信息

Owens David, Vora Jiten

机构信息

Diabetes Research Unit, First Floor, Academic Centre, Llandough Hospital, Penlarn Road, Penarth, South Glamorgan, CF64 2FX, Wales, UK. owens

出版信息

Expert Opin Drug Metab Toxicol. 2006 Oct;2(5):793-804. doi: 10.1517/17425255.2.5.793.

Abstract

Insulin aspart, an analogue of human insulin, which is approved for use in people with diabetes, is more rapidly absorbed and achieves higher plasma concentrations than human soluble insulin following subcutaneous injection. Hence, it has a faster and more effective glucose-lowering action, with superior control of postprandial hyperglycaemia compared with human soluble insulin. Its shorter duration of action makes interprandial and nocturnal hypoglycaemia less of a problem than with human soluble insulin. Insulin aspart is approved for use in continuous subcutaneous infusion and offers a valuable treatment option during pregnancy.

摘要

门冬胰岛素是一种人胰岛素类似物,已被批准用于糖尿病患者,皮下注射后,它比人可溶性胰岛素吸收更快,血浆浓度更高。因此,它具有更快、更有效的降糖作用,与可溶性人胰岛素相比,能更好地控制餐后高血糖。与可溶性人胰岛素相比,其作用持续时间较短,使得餐间和夜间低血糖问题较少。门冬胰岛素已被批准用于持续皮下输注,并且是孕期一种有价值的治疗选择。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验